|
1
|
Fisher B, Costantino JP, Wickerham DL,
Redmond CK, Kavanah M and Cronin WM: Tamoxifen for prevention of
breast cancer: report of the National Surgical Adjuvant Breast and
Bowel Project P-1 Study. J Natl Cancer Inst. 90:1371–1388. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Powles T, Eeles R, Ashley SE, Easton D,
Chang J and Dowsett L: Interim analysis of the incidence of breast
cancer in the Royal Marsden Hospital tamoxifen randomized
chemoprevention trial. Lancet. 352:98–101. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Veronesi U, Maisonneuve P, Sacchini V,
Rotmensz N and Boyle P: Tamoxifen for breast cancer among women
hysterectomised. Lancet. 359:1122–1124. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Forbes JF, Cuzick J, Buzdar A, Howell A,
Tobias JS and Baum M: Arimidex, tamoxifen, alone or in combination
(ATAC) trialists' group. Effect of anastrozole and tamoxifen as
adjuvant treatment for early-stage breast cancer: 100-month
analysis of the ATAC trial. Lancet Oncol. 9:45–53. 2008.
|
|
5
|
Li Y and Brown PH: Prevention of
ER-negative breast cancer. Recent Results Cancer Res. 181:121–134.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fosslien E: Molecular pathology of
cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci. 30:3–21.
2000.PubMed/NCBI
|
|
7
|
Dempke W, Rie C, Grothey A and Schmoll H:
Cyclooxygenase-2: a novel target for cancer chemotherapy. J Cancer
Res Clin Oncol. 127:411–417. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Krcova Z, Ehrmann J, Krejci V, Eliopoulos
A and Kolar Z: TPL-2/COT and COX-2 in breast cancer. Biomed Pap Med
Fac Univ Palacky Olomouc Czech Repub. 152:21–25. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Martínez-Arribas F, Martín-Garabato E,
Zapardiel I, Sánchez J, Lucas AR, Tejerina A and Schneider J: Bax
expression in untreated breast cancer: an immunocytometric study of
255 cases. Anticancer Res. 28:2595–2598. 2008.PubMed/NCBI
|
|
10
|
Singh B, Cook KR, Vincent L, Hall CS,
Berry JA, Multani AS and Lucci A: Cyclooxygenase-2 induces genomic
instability, BCL2 expression, doxorubicin resistance, and altered
cancer-initiating cell phenotype in MCF7 breast cancer cells. J
Surg Res. 147:240–246. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhu XG, Tao L, Mei ZR, Wu HP and Jiang ZW:
Aspisol inhibits tumor growth and induces apoptosis in breast
cancer. Exp Oncol. 30:289–294. 2008.PubMed/NCBI
|
|
12
|
Ristimäki A, Sivula A, Lundin J, Lundin M,
Salminen T, Haglund C, Joensuu H and Isola J: Prognostic
significance of elevated cyclooxygenase-2 expression in breast
cancer. Cancer Res. 62:632–635. 2002.PubMed/NCBI
|
|
13
|
Boland GP, Butt IS, Prasad R, Knox WF and
Bundred NJ: COX-2 expression is associated with an aggressive
phenotype in ductal carcinoma in situ. Br J Cancer. 90:423–429.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sheen-Chen SM, Chou FF, Hsu W, Huang CC,
Eng HL and Tang RP: Lack of prognostic value of insulin-like growth
factor-1 in patients with breast cancer: analysis with tissue
microarray. Anticancer Res. 27:3541–3544. 2007.PubMed/NCBI
|
|
15
|
Werner H and Bruchim I: The insulin-like
growth factor-1 receptor on the oncogene. Arch Physiol Biochem.
115:58–71. 2009. View Article : Google Scholar
|
|
16
|
Levitt RJ, Buckley J, Blouin MJ, Schaub B,
Triche TJ and Pollak M: Growth inhibition of breast epithelial
cells by celecoxib is associated with up-regulation of insulin-like
growth factor binding protein-3 expression. Biochem Biophys Res
Commun. 316:421–428. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Põld M, Krysan K, Põld A, Dohadwala M,
Heuze-Vourc'h N, Mao JT, Riedl KL, Sharma S and Dubinett SM:
Cyclooxygenase-2 modulates the insulin-like growth factor axis in
non-small-cell lung cancer. Cancer Res. 64:6549–6555.
2004.PubMed/NCBI
|
|
18
|
Dabbs DJ: Ductal carcinoma of the breast:
nuclear grade as a predictor of S-phase fraction. Human Pathol.
24:652–656. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Elston CW and Ellis IO: Pathological
prognostic factors in breast cancer I. The value of histological
grade in breast cancer: experience from a large study with
long-term follow-up. Histopathology. 19:403–410. 1991. View Article : Google Scholar
|
|
20
|
Wolff AC, Hammond ME, Schwartz JN, Hagerty
KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer
A, et al; American Society of Clinical Oncology; College of
American Pathologists. American Society of Clinical
Oncology/College of American Pathologists guideline for human
epidermal growth factor receptor 2 testing in breast cancer. J Clin
Oncol. 25:118–145. 2006. View Article : Google Scholar
|
|
21
|
Shim JY, Jung An H, Lee YH, Kim SK, Lee KP
and Lee KS: Over-expression of Cyclooxygenase-2 is associated with
breast carcinoma and its poor prognostic factors. Mod Pathol.
16:1199–1204. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Oliveira VM, Piato S and Silva MA:
Correlation of cyclooxygenase-2 and aromatase immunohistochemical
expression in invasive ductal carcinoma, ductal carcinoma in situ,
and adjacent normal epithelium. Breast Cancer Res Treat.
95:235–241. 2006. View Article : Google Scholar
|
|
23
|
Bernard R: Fundamentals of Biostatistics.
2nd edition. Buxbury Press; Boston, MA: 1986
|
|
24
|
Hwang D, Scollard D, Byrne J and Levine E:
Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast
cancer. J Natl Cancer Inst. 90:455–460. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Buskens CJ, Sivula A, van Rees BP, Haglund
C, Offerhaus GJ, van Lanschot JJ and Ristimäki A: Comparison of
cyclooxygenase 2 expression in adenocarcinomas of the gastric
cardia and distal esophagus. Gut. 52:1678–1683. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Singh-Ranger G, Salhab M and Mokbel K: The
role of cyclooxygenase-2 in breast cancer: review. Breast Cancer
Res Treat. 109:189–198. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Davies G, Salter J, Hills F, Martin L,
Sacks N and Dowset M: Correlation of cyclooxygenase-2 expression
and angiogenesis in human breast cancer. Clin Cancer Res.
9:2652–2656. 2003.
|
|
28
|
Half E, Tang XT, Gwyn K, Sahin A, Wathen K
and Sinicrope FA: Cyclooxygenase-2 expression in human breast
cancers and adjacent ductal carcinoma in situ. Cancer Res.
62:1676–1681. 2002.PubMed/NCBI
|
|
29
|
Tan KB, Yong WP and Putti TC:
Cyclooxygenase-2 expression: a potential prognostic and predictive
marker for high-grade ductal carcinoma in situ of the breast.
Histopathology. 44:24–28. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Perrone G, Santini D, Vincenzi B, Zagami
M, La Cesa A, Bianchi A, Altomare V, Primavera A, Battista C,
Vetrani A, Tonini G and Rabitti C: COX-2 expression in DCIS:
correlation with VEGF, HER-2/neu, prognostic molecular markers and
clinicopathological features. Histopathology. 46:561–568. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Howe LR, Subbaramaiah K, Brown AM and
Dannenberg AJ: Cyclooxygenase-2: a target for prevention and
treatment of breast cancer. Endocr Relat Cancer. 8:97–114. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Benoit V, Relic B, Leval X, Chariot A,
Merville MP and Bours V: Regulation of HER-2 oncogene expression by
cyclooxygenase-2 and prostaglandin E2. Oncogene. 23:1631–1635.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang L, Liu LH, Shan BE, Zhang C, Sang MS
and Li J: Celecoxib promotes apoptosis of breast cancer cell line
MDA-MB-231 through down-regulation of the NK-κB pathway. Chin J
Cancer. 28:569–574. 2009.PubMed/NCBI
|
|
34
|
Li RX, Shi F, Wu YY, Wu Y, Guo JJ and Dong
DF: The relationship between lymphatic metastasis and serum
vascular endothelial growth factor C and cyclooxygenase 2
expression in breast cancer. Zhonghua Yi Xue Za Zhi. 88:88–91.
2008.PubMed/NCBI
|
|
35
|
Yang L, Zhu X and Ran L: Correlations of
HER-2, PCNA, Bcl-2, and Bax expression to prognosis of breast
cancer. Ai Zheng. 26:756–761. 2007.(In Chinese).
|
|
36
|
Mintz PJ, Habib NA, Jones LJ, Giamas G,
Lewis JS, Bowen RL, Coombes RC and Stebbing J: The phosphorylated
membrane estrogen receptor and cytoplasmic signaling and apoptosis
proteins in human breast cancer. Cancer. 113:1489–1495. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Martínez-Arribas F, Nuñez-Villar MJ, Lucas
AR, Sanchez J, Tejerina A and Schneider J: Immunofluorometric study
of Bcl-2 and BAX expression in clinical fresh tumor samples from
breast cancer patients. Anticancer Res. 23:565–568. 2003.PubMed/NCBI
|
|
38
|
Arun B, Kilic G, Yen C, et al: Loss of
FHIT expression in breast cancer is correlated with poor prognostic
markers. Cancer Epidemiol Biomarkers Prev. 14:1681–1685. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Michael MS, Badr MZ and Badawi AF:
Inhibition of cyclooxygenase-2 and activation of peroxisome
proliferator-activated receptor-γ synergistically induces apoptosis
and inhibits growth of human breast cancer cells. Int J Mol Med.
11:733–736. 2003.
|
|
40
|
Hoque A, Menter DG, Sahin AA, Sneige N and
Lippman SM: No increased Ki67 expression in ductal carcinoma in
situ associated with invasive breast cancer. Cancer Epidemiol
Biomarkers Prev. 10:153–154. 2001.PubMed/NCBI
|
|
41
|
Mylonas I, Makovitzky J, Jeschke U, Briese
U, Friese K and Gerber B: Expression of Her2/neu, steroid receptors
(ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma
associated with ductal carcinoma in situ (DCIS) versus invasive
breast cancer alone. Anticancer Res. 25:1719–1723. 2005.
|
|
42
|
Faratian D, Munro A, Twelves C and
Bartlett JM: Membranous and cytoplasmic staining of Ki67 is
associated with HER2 and ER status in invasive breast carcinoma.
Histopathology. 54:254–257. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shimizu C, Hasegawa T, Tani Y, Takahashi
F, Takeuchi M, Watanabe T, Ando M, Katsumata N and Fujiwara Y:
Expression of insulin-like growth factor 1 receptor in primary
breast cancer: immunohistochemical analysis. Hum Pathol.
35:1537–1542. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhang H, Sachdev D, Wang C, Hubel A,
Gaillard-Kelly M and Yee D: Detection and downregulation of type I
IGF receptor expression by antibody-conjudated quantum dots in
breast cancer cells. Breast Cancer Res Treat. 114:277–285. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ellis MJ, Jenkins S, Hanfelt J, Redington
ME, Taylor M, Leek R, Siddle K and Harris A: Insulin-like growth
factors in human breast cancer. Breast Cancer Res Treat.
52:175–184. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Law JH, Habibi G, Hu K, Masoudi H, Wang
MY, Stratford AL, Park E, Gee JM, Finlay P, Jones HE, et al:
Phosphorylated insulin-like growth factor-1/insulin receptor is
present in all breast cancer subtypes and is related to poor
survival. Cancer Res. 68:10238–103246. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Henriksen KL, Rasmussen BB, Lykkesfeldt
AE, Moller S, Ejlertsen B and Mouridsen HT: Semi-quantitative
scoring of potentially predictive markers for endocrine treatment
of breast cancer: a comparison between whole sections and tissue
microarrays. J Clin Pathol. 60:397–404. 2007. View Article : Google Scholar
|
|
48
|
Levitt R and Pollak M: Insulin-like growth
factor-I antagonizes the antiproliferative effects of
cyclooxygenase-2 inhibitors on BxPC-3 pancreatic cancer cells.
Cancer Res. 62:7372–7376. 2002.PubMed/NCBI
|
|
49
|
Jin Q and Esteva FJ: Cross-talk between
the ErbB/HER family and the type I insulin-like growth factor
receptor signaling pathway in breast cancer. J Mammary Gland Biol
Neoplasia. 13:485–498. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zakikhani M, Blouin MJ, Piura E and Pollak
MN: Metformin and rapamycin have distinct effects on the AKT
pathway and proliferation in breast cancer cells. Breast Cancer Res
Treat. 123:271–279. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Jiralerspong S, Palla SL, Giordano SH,
Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi
GN and Gonzalez-Angulo AM: Metformin and pathologic complete
responses to neoadjuvant chemotherapy in diabetic patients with
breast cancer. J Clin Oncol. 27:3297–3302. 2009. View Article : Google Scholar : PubMed/NCBI
|
